fenoldopam has been researched along with Blood Pressure, Low in 3 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients with acute kidney injury after cardiac surgery, fenoldopam infusion, compared with placebo, did not reduce the need for renal replacement therapy or risk of 30-day mortality but was associated with an increased rate of hypotension." | 9.19 | Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. ( Alvaro, G; Amantea, B; Baldassarri, R; Bellomo, R; Bove, T; Calabrò, MG; Camata, A; Caramelli, F; Cariello, C; Comis, M; Conte, M; Dal Checco, E; Faita, L; Frontini, M; Galdieri, N; Guarracino, F; Landoni, G; Lembo, R; Maglioni, E; Martinez, B; Pala, G; Pappalardo, F; Pasero, DC; Paternoster, G; Persi, B; Pinelli, F; Pisano, A; Renzini, M; Saleh, O; Scandroglio, AM; Verdecchia, C; Zangrillo, A; Zucchetti, MC, 2014) |
| "Fenoldopam, a selective dopamine1 receptor agonist, has been recommended for induced hypotension because it effectively lowers arterial blood pressure and improves renal perfusion." | 7.68 | Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. ( Jaffe, RS; Kien, ND; Moore, PG, 1992) |
| "Among patients with acute kidney injury after cardiac surgery, fenoldopam infusion, compared with placebo, did not reduce the need for renal replacement therapy or risk of 30-day mortality but was associated with an increased rate of hypotension." | 5.19 | Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. ( Alvaro, G; Amantea, B; Baldassarri, R; Bellomo, R; Bove, T; Calabrò, MG; Camata, A; Caramelli, F; Cariello, C; Comis, M; Conte, M; Dal Checco, E; Faita, L; Frontini, M; Galdieri, N; Guarracino, F; Landoni, G; Lembo, R; Maglioni, E; Martinez, B; Pala, G; Pappalardo, F; Pasero, DC; Paternoster, G; Persi, B; Pinelli, F; Pisano, A; Renzini, M; Saleh, O; Scandroglio, AM; Verdecchia, C; Zangrillo, A; Zucchetti, MC, 2014) |
| "Fenoldopam, a selective dopamine1 receptor agonist, has been recommended for induced hypotension because it effectively lowers arterial blood pressure and improves renal perfusion." | 3.68 | Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. ( Jaffe, RS; Kien, ND; Moore, PG, 1992) |
| "Fenoldopam is a dopamine receptor alpha1-specific agonist that increases renal blood flow in patients with kidney failure." | 2.71 | Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. ( Cotsonis, G; Finkel, KW; Murray, PT; Samuels, J; Shaw, AD; Tumlin, JA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bove, T | 1 |
| Zangrillo, A | 1 |
| Guarracino, F | 1 |
| Alvaro, G | 1 |
| Persi, B | 1 |
| Maglioni, E | 1 |
| Galdieri, N | 1 |
| Comis, M | 1 |
| Caramelli, F | 1 |
| Pasero, DC | 1 |
| Pala, G | 1 |
| Renzini, M | 1 |
| Conte, M | 1 |
| Paternoster, G | 1 |
| Martinez, B | 1 |
| Pinelli, F | 1 |
| Frontini, M | 1 |
| Zucchetti, MC | 1 |
| Pappalardo, F | 1 |
| Amantea, B | 1 |
| Camata, A | 1 |
| Pisano, A | 1 |
| Verdecchia, C | 1 |
| Dal Checco, E | 1 |
| Cariello, C | 1 |
| Faita, L | 1 |
| Baldassarri, R | 1 |
| Scandroglio, AM | 1 |
| Saleh, O | 1 |
| Lembo, R | 1 |
| Calabrò, MG | 1 |
| Bellomo, R | 1 |
| Landoni, G | 1 |
| Tumlin, JA | 1 |
| Finkel, KW | 1 |
| Murray, PT | 1 |
| Samuels, J | 1 |
| Cotsonis, G | 1 |
| Shaw, AD | 1 |
| Kien, ND | 1 |
| Moore, PG | 1 |
| Jaffe, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.[NCT00621790] | Phase 3 | 667 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial[NCT00286403] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn (stopped due to The study was terminated due to logistics at a local hospital.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fenoldopam and Blood Pressure, Low
| Article | Year |
|---|---|
Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.
Topics: Acute Kidney Injury; Aged; Cardiac Surgical Procedures; Creatinine; Critical Illness; Double-Blind M | 2014 |
Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Creatinine; Diabetes Complications; Disease Progression; Dopamine Agonists; Double-Blind Method; Ear | 2005 |
1 other study available for fenoldopam and Blood Pressure, Low
| Article | Year |
|---|---|
Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Anesthesia, Inhalation; Animals; Dogs; F | 1992 |